文献速递哮喘慢阻肺

哮喘-慢阻肺重叠急性加重期临床与炎症表型可预测院内不良结局

Clinical and Inflammatory Phenotypes During Exacerbations Predict In-Hospital Adverse Outcomes in Asthma-COPD Overlap.
PubMed 文献 · Respirology · 2026-06-23

本研究为前瞻性两中心队列,纳入2444例哮喘-慢阻肺重叠急性加重(EACO)住院患者,用无监督k-means聚类识别炎症表型并评估其与院内结局的关联。共识别3种表型,其中中性粒细胞/淋巴细胞比值升高的低嗜酸粒细胞全身炎症型(T1)复合不良结局率最高(24.2%,p<0.001);基于血生物标志物的列线图预测性能良好(训练AUC=0.775,验证AUC=0.766)。

要点

  • EACO住院患者可聚类为T1低嗜酸粒细胞全身炎症型、T2嗜酸粒细胞型、T3嗜酸-中性粒平衡型三种炎症表型。
  • T1型全身炎症指标升高且复合不良结局率最高(24.2%,p<0.001),中性粒细胞主导表型风险最高。
  • 中性粒细胞绝对值、D-二聚体、淋巴细胞绝对值为结局关键预测因子,列线图AUC训练0.775、验证0.766。

核心结论

  • EACO急性加重期炎症表型可预测不同的院内结局,中性粒细胞主导表型风险最高。
  • 基于简单血液生物标志物的早期表型风险分层可能指导EACO个体化管理。

研究设计与样本

  • 前瞻性两中心队列研究,纳入2444例EACO患者(含训练队列与验证队列)。
  • 采用无监督k-means聚类识别炎症表型,并行排除人口学变量的敏感性分析。
  • 用逻辑回归与因果中介分析评估表型-结局关联,并以ROC曲线(AUC)开发及验证列线图。

主要发现

  • 识别出3种表型:Cluster T1(NLR升高、低嗜酸粒细胞性全身炎症)、Cluster T2(嗜酸粒细胞型)、Cluster T3(嗜酸-中性粒平衡型)。
  • Cluster T1表现为全身炎症亢进(白细胞计数、中性粒细胞、NLR、CRP、PCT、IL-6升高),复合不良结局率最高(24.2%,p<0.001)。
  • 逻辑回归显示中性粒细胞绝对值(β=0.38,p<0.001)、D-二聚体(β=0.25,p<0.001)、淋巴细胞绝对值(β=-0.41,p<0.001)为结局关键预测因子,并经因果中介分析确认。
  • 列线图预测性能稳健:训练AUC=0.775,验证AUC=0.766。

关键数值与推荐

  • 院内临床结局包括ICU入住、有创通气、院内死亡。
  • Cluster T1复合不良结局率为24.2%(p<0.001)。
  • 中性粒细胞绝对值β=0.38(p<0.001)、D-二聚体β=0.25(p<0.001)、淋巴细胞绝对值β=-0.41(p<0.001)。
  • 列线图AUC:训练队列0.775,验证队列0.766。

临床怎么用

  • 对EACO住院患者可依据血常规及CRP、PCT、IL-6、D-二聚体等简单标志物早期识别炎症表型。
  • 对中性粒细胞主导的低嗜酸粒细胞全身炎症型(T1)应提高警惕,加强院内不良结局监测。
  • 可借助列线图进行表型化风险分层,辅助个体化EACO管理决策。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Exacerbations of asthma-chronic obstructive pulmonary disease overlap (EACO) are associated with high mortality, yet the acute-phase heterogeneity remains poorly characterized. This study aimed to identify distinct inflammatory phenotypes of EACO during hospitalization and evaluate their associations with clinical outcomes. METHODS: A prospective two-centre cohort study enrolled 2444 EACO patients (training and validation cohort). Baseline inflammatory markers and clinical data were collected. Unsupervised k-means clustering identified inflammatory phenotypes, with sensitivity analysis excluding demographic variables. In-hospital clinical outcomes (ICU admission, invasive ventilation, in-hospital mortality) were assessed. Logistic regression and causal mediation analysis evaluated phenotype-outcome associations. A nomogram was developed and validated using receiver operating characteristic curves (AUC). RESULTS: Three distinct phenotypes were identified: Cluster T1 (neutrophil-to-lymphocyte ratio [NLR]-elevated hypoeosinophilic systemic inflammatory), Cluster T2 (eosinophilic), and Cluster T3 (eosinophil-neutrophil balanced). Cluster T1 exhibited systemic hyperinflammation (elevated white blood cell count, neutrophils, NLR, C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6)), and the highest composite adverse outcome rate (24.2%; p < 0.001). Logistic regression revealed absolute neutrophil count (β = 0.38, p < 0.001), D-dimer (β = 0.25, p < 0.001), and absolute lymphocyte count (β = -0.41, p < 0.001) as key outcome predictors, confirmed by causal mediation analysis. The nomogram showed robust predictive performance (AUC training = 0.775; validation = 0.766). CONCLUSION: Inflammatory phenotypes during EACO predict differential in-hospital outcomes, with neutrophil-dominant phenotypes conferring the highest risk. Early phenotype-based risk stratification using simple blood biomarkers may guide individualized EACO management.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Yuan, Wang, Yuan, et al. Clinical and Inflammatory Phenotypes During Exacerbations Predict In-Hospital Adverse Outcomes in Asthma-COPD Overlap. Respirology. 2026. PMID: 42337860. doi:10.1002/resp.70275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。